Immuno-Oncology Drugs Elotuzumab, Anti-LAG-3 and Anti-TIGIT

Active:	No
Cancer Type:	Multiple Myeloma	NCT ID:	NCT04150965
Trial Phases:	Phase I Phase II	Protocol IDs:	MyCheckpoint (MMRC-089) (primary) MMRC-089 Anti LAG3/Anti TIGIT NCI-2019-07957
Eligibility:	18 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	Multiple Myeloma Research Consortium
NCI Full Details:	http://clinicaltrials.gov/show/NCT04150965

Summary

This a Phase I/II randomized trial for patients with relapsed refractory Multiple Myeloma who
have relapsed after treatment with prior therapies. The protocol is designed to evaluate two
agents, Anti-LAG-3 and Anti-TIGIT, in order to understand their immunologic effects and
safety both as single agents and in combination with pomalidomide and dexamethasone. In these
arms, patients will be treated with either Anti-LAG-3 or Anti-TIGIT respectively for one
cycle as single agent followed by the addition of pomalidomide and dexamethasone in
combination for subsequent cycles.

A third arm allows patients to be treated with the FDA approved combination of elotuzumab
plus pomalidomide and dexamethsone as a control. This arm will thus allow a concurrent
standard of care comparator for the experimental arms.

Objectives

This study will enroll 104 patients to one of three treatment arms. The study is open to
patients relapsing with refractory Multiple Myeloma who have:

- received 3 prior lines of therapy

- exposed to each of these 3 drug classes:

- IMiD

- proteasome inhibitors, and

- anti-CD38 monoclonal antibody

- relapsed and refractory are defined using the IMWG criteria:

- disease that is non-responsive while on salvage therapy or progresses within 60
days of last therapy in patients who have achieved minimal response or better at
some point previously to then progressing in their disease course.

Treatment Sites in Georgia

Emory University Hospital - Atlanta
1364 Clifton Road NE
Atlanta, GA 30322
www.emoryhealthcare.org

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.